Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,099 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Culprit lesion location and outcomes in patients with multivessel disease and infarct-related cardiogenic shock: a core laboratory analysis of the CULPRIT-SHOCK trial.
Hauguel-Moreau M, Barthélémy O, Farhan S, Huber K, Rouanet S, Zeitouni M, Guedeney P, Hage G, Vicaut E, Zeymer U, Desch S, Thiele H, Montalescot G. Hauguel-Moreau M, et al. Among authors: huber k. EuroIntervention. 2021 Aug 6;17(5):e418-e424. doi: 10.4244/EIJ-D-20-00561. EuroIntervention. 2021. PMID: 32894227 Free PMC article. Clinical Trial.
Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction.
Huber K, De Caterina R, Kristensen SD, Verheugt FW, Montalescot G, Maestro LB, Van de Werf F; Task Force on Pre-hospital Reperfusion Therapy of the Working Group on Thrombosis of the ESC. Huber K, et al. Eur Heart J. 2005 Oct;26(19):2063-74. doi: 10.1093/eurheartj/ehi413. Epub 2005 Jul 29. Eur Heart J. 2005. PMID: 16055497 Review. No abstract available.
Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors.
De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip D, Maioli M, Zorman S, Mesquita Gabriel H, Emre A, Rakowski T, Gyongyosi M, Huber K, Van't Hof AW. De Luca G, et al. Among authors: huber k. Atherosclerosis. 2009 Nov;207(1):181-5. doi: 10.1016/j.atherosclerosis.2009.03.042. Epub 2009 Apr 5. Atherosclerosis. 2009. PMID: 19426981
The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention.
Ross AM, Huber K, Zeymer U, Armstrong PW, Granger CB, Goldstein P, Bogaerts K, Van de Werf F. Ross AM, et al. Among authors: huber k. JACC Cardiovasc Interv. 2009 Oct;2(10):925-30. doi: 10.1016/j.jcin.2009.08.009. JACC Cardiovasc Interv. 2009. PMID: 19850250 Free article.
Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial.
Jarai R, Huber K, Bogaerts K, Droogne W, Ezekowitz J, Granger CB, Sinnaeve PR, Ross AM, Zeymer U, Armstrong PW, Van de Werf FJ; ASSENT IV-PCI investigators. Jarai R, et al. Among authors: huber k. Am Heart J. 2010 Jan;159(1):131-40. doi: 10.1016/j.ahj.2009.11.001. Am Heart J. 2010. PMID: 20102879 Clinical Trial.
Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone [corrected] concentrations in ST elevation myocardial infarction: an analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial.
Jarai R, Huber K, Bogaerts K, Sinnaeve PR, Ezekowitz J, Ross AM, Zeymer U, Armstrong PW, Van de Werf FJ; ASSENT-4 PCI investigators. Jarai R, et al. Among authors: huber k. Crit Care Med. 2010 Sep;38(9):1793-801. doi: 10.1097/CCM.0b013e3181eaaf2a. Crit Care Med. 2010. PMID: 20562693 Clinical Trial.
2,099 results